Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.94% | 0.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.94% | 0.62% | |||
| Cost of Revenue | 1.24% | 3.68% | |||
| Gross Profit | 2.11% | -0.06% | |||
| SG&A Expenses | 17.32% | -1.06% | |||
| Depreciation & Amortization | 552.65% | 91.02% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 40.91% | 1.93% | |||
| Operating Income | -789.58% | -20.26% | |||
| Income Before Tax | -433.18% | -4.79% | |||
| Income Tax Expenses | 75.19% | -128.36% | |||
| Earnings from Continuing Operations | -369.53% | 322.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -369.53% | 322.65% | |||
| EBIT | -789.58% | -20.26% | |||
| EBITDA | -81.30% | 13.90% | |||
| EPS Basic | -364.96% | 318.40% | |||
| Normalized Basic EPS | -433.21% | -12.37% | |||
| EPS Diluted | -387.65% | 292.63% | |||
| Normalized Diluted EPS | -457.81% | -13.86% | |||
| Average Basic Shares Outstanding | 1.72% | 1.03% | |||
| Average Diluted Shares Outstanding | -5.27% | 2.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||